E-MTAB-6486 - RNA-seq to investigate impact of treatment of KRAS mutant NCI-H2009 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib

Status
Submitted on 1 June 2016, released on 1 June 2018, last updated on 16 March 2020
Organism
Homo sapiens
Samples (6)
Protocols (7)
Description
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we examined the transcriptional impact of treatment of KRAS mutant human lung cancer cell lines with the multi-ERBB inhibitor Neratinib
Experiment types
RNA-seq of coding RNA, compound treatment design
Contact
Citation
The ERBB network facilitates KRAS-driven lung tumorigenesis. Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, Le Quesne J, Dick C, Vousden KH, Martins CP, Murphy DJ. Science Translational Medicine 10(468) (2018)
MINSEQE
Exp. designProtocolsVariablesProcessedSeq. reads
Files
Investigation descriptionE-MTAB-6486.idf.txt
Sample and data relationshipE-MTAB-6486.sdrf.txt
Links